FGFR4 and hepatocellular carcinoma: FGF401, another FGFR4 inhibitor, was investigated as a monotherapy or in combination with PDR001 in HCC patients with positive FGFR4 and KLB (a FGF19 co-receptor) expression (NCT02325739).